The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy Ministry ...
Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...
Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...
Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved tumor treating fields for use as part of combination treatment for certain patients with ...
A Des Moines microbrewery is a finalist for the best brewpubs across the U.S., and Iowans have a chance to vote it into the top 10. Lua Brewing was nominated for USA TODAY 10Best's Readers' Choice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback